Context Therapeutics Inc.

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

CNTX$0.20+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	March 31, 2025	December 31, 2024
	(Unaudited)	(Note 3)
Assets
Current assets:
Cash and cash equivalents	$89,352,227	$94,429,824
Prepaid expenses and other current assets	3,378,600	3,466,160
Total current assets	92,730,827	97,895,984
Property and equipment, net	41,852	11,959
Operating lease right-of-use lease asset	192,804	218,816
Total assets	$92,965,483	$98,126,759
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,001,283	$1,452,188
Accrued expenses and other current liabilities	787,776	1,188,929
Operating lease liability - current	111,098	107,316
Total current liabilities	1,900,157	2,748,433
Operating lease liability - non-current	82,608	112,064
Total liabilities	1,982,765	2,860,497
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding	—	—
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2025 and December 31, 2024; 89,704,194 shares issued and outstanding at March 31, 2025 and December 31, 2024	89,704	89,704
Additional paid-in capital	190,249,969	189,956,252
Accumulated deficit	(99,356,955)	(94,779,694)
Total stockholders' equity	90,982,718	95,266,262
Total liabilities and stockholders' equity	$92,965,483	$98,126,759

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.